{{roughtranslation|time=2012-06-11T07:00:58+00:00}}
{{medical}}
{{Drugbox
| verifiedrevid = 459435450
| IUPAC_name = (''RS'')-''N'',''N''-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
| image = Cyclophosphamid.svg
| width = 150
| image2 = R-cyclophosphamide-from-xtal-1996-3D-balls.png

<!--Clinical data-->
| tradename = Lyophilizedcytoxan
| Drugs.com = {{drugs.com|monograph|cyclophosphamide}}
| MedlinePlus = a682080
| pregnancy_AU = D
| pregnancy_US = D
| pregnancy_category =  
| legal_status = Rx-only
| dependency_liability =  
| routes_of_administration = Oral, [[Intravenous_therapy|intravenous]]

<!--Pharmacokinetic data-->
| bioavailability = >75% (oral)
| protein_bound = >60%
| metabolism = [[Liver|Hepatic]]
| elimination_half-life = 3-12 hours
| excretion = [[Kidney|Renal]]

<!--Chemical data-->
| C=7 | H=15 | Cl=2 | N=2 | O=2 | P=1 
| molecular_weight = 261.086 [[克|g]]/[[摩尔_(单位)|mol]]
| smiles = O=P1(OCCCN1)N(CCCl)CCCl
| InChI = 1/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)
| InChIKey = CMSMOCZEIVJLDB-UHFFFAOYAB
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00531
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 6UXW23996M
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 4027
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07760
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 88
| ChemSpiderID = 2804
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 50-18-0
| ATC_prefix=L01
| ATC_suffix=AA01
| ATC_supplemental=
| StdInChI = 1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = CMSMOCZEIVJLDB-UHFFFAOYSA-N
| density =  
| melting_point = 2
| boiling_point =  
| solubility =  
| specific_rotation =  
| sec_combustion =  
}}

'''环磷酰胺'''（Cyclophosphamide）。<ref name="cytophosphane">[http://www.cancer.gov/drugdictionary/?CdrID=39748 Cyclophosphamide]，National Cancer Dictionary</ref>為oxazophorines的衍生物。

==作用機轉==
其藥物化學機制為<ref name=Foye>{{Cite book | author =Thomas L. Lemke, David A. Williams | title =Foye's Principles of Medicinal Chemistry | location = USA |chapter=Cancer and Chemotherapy| publisher = LWW| date = 2012 | pages = 1199-1226 | ISBN = 978-1609133450 | accessdate = 2017-05-29  | language = en }} </ref>:

#經過[[CYP450|CYP450]]中的 CYP3A4或CYP2B6，大概約90%的服用劑量被生物轉化，接上[[醇|醇]]基形成 Carbinolamide，然後轉運入[[細胞|細胞]]內（但也有些沒轉運入[[細胞|細胞]]內）
#在[[血液|血液]]內或[[細胞|細胞]]內[[水解|水解]]成Aldophosphamide，在[[血液|血液]]內的經[[水解|水解]]後轉運入[[細胞|細胞]]內
#分解產生Phsophoramide mustard（然後作用於DNA上，類似[[氮芥|氮芥]]）和具有[[膀胱|膀胱]]與[[神經|神經]][[毒性|毒性]]的Acrolein
#接著，
##Phsophoramide mustard走圖中下方路徑，環化形成四級Aziridinium[[離子|離子]]，在[[酸鹼值|酸鹼值]]為7.4環境下為主要活性產物
##Phsophoramide mustard走圖中右方路徑，分解產生[[磷酸|磷酸]]、[[氨|氨]]和Bis(β-chloroethyl)amine，接下來的路徑可參考[[氮芥|氮芥]][[File:Cyclophosphamide_mechanism.svg|center]]

== 醫藥應用 ==
由於环磷酰胺具有減低或停止細胞生長的功能，所以常和其他免疫抑制劑一起用來治療[[淋巴瘤|淋巴瘤]] 、某些[[腦癌|腦癌]]、[[白血病|白血病]]<ref name="leukemia">[http://dx.doi.org/10.1002%2Fcncr.22662 Shanafelt TD, Lin T, Geyer SM, et al. (June 2007). ]，"Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia". Cancer 109 (11): 2291–8.</ref>，及一些實質固態瘤症狀。<ref name="solid tumor">[http://www.ncbi.nlm.nih.gov/pubmed/16707607 Young SD, Whissell M, Noble JC, et al. (2006). ]，"Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors and". Clinical Cancer Research 12 (10): 3092–8.</ref>

== 副作用 ==
許多的病患在服用环磷酰胺後，產生嚴重的副作用，包括噁心、嘔吐、骨髓抑制、胃痛、下瀉、禿頭、嗜睡等。[[出血性膀胱炎|出血性膀胱炎]]也經常出現，但可以經由適當的攝取液體跟服用[[美司钠|美司钠]]來補充[[硫氫基|硫氫基]]而鍵結到[[丙烯醛|丙烯醛]]上，進一步預防出血性膀胱炎的副作用。

环磷酰胺本身也是致癌物質，長期使用可能會有轉移性的膀胱癌發生。也會使得身體對抗感染的能力下降。

== 参考文献 ==
{{reflist|2}}

==外部連結==
* [http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Cyclophosphamide+(anhydrous) U.S. National Library of Medicine: Drug Information Portal - Cyclophosphamide]

{{化疗药物}}
[[Category:酰胺|Category:酰胺]]